Flinton Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Flinton Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$324K	Buy	1,187 +167	+16%	+$61.2K	0.01%	569
2019 Q2	$544K	Sell	1,020 -349	-25%	-$175K	0.02%	456
2019 Q1	$690K	Sell	1,369 -3,255	-70%	-$1.93M	0.02%	377
2018 Q4	$2.28M	Buy	4,624 +881	+24%	+$532K	0.09%	181
2018 Q3	$3.42M	Buy	3,743 +3,312	+768%	+$2.83M	0.11%	165
2018 Q2	$316K	Buy	431 +293	+212%	+$338K	0.01%	545
2018 Q1	$219K	Sell	138 -594	-81%	-$765K	0.01%	624
2017 Q4	$655K	Buy	732 +125	+21%	+$73.9K	0.02%	379
2017 Q3	$218K	Buy	607 +82	+16%	+$25.7K	0.01%	597
2017 Q2	$154K	Buy	525 +226	+76%	+$65.3K	0.01%	644
2017 Q1	$105K	Buy	299 +30	+11%	+$6.74K	﹤0.01%	619
2016 Q4	$49K	Buy	+269	New	+$54.7K	﹤0.01%	721

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Flinton Capital Management's NKTR Position: Q3 2019 in Review

Flinton Capital Management increased its Nektar Therapeutics (NKTR) stake by 16% in Q3 2019, buying an estimated $61.2K and bringing the position to 1,187 shares worth $324K. The position accounts for 0.01% of the portfolio, ranked #569.

Flinton Capital Management first reported a position in NKTR in Q4 2016 and has held it in 12 quarters since. The position peaked at $3.42M in Q3 2018. 287 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

Flinton Capital Management held 1,187 shares of Nektar Therapeutics worth $324K as of Q3 2019.
Flinton Capital Management bought 167 Nektar Therapeutics shares in Q3 2019, an estimated $61.2K.
Nektar Therapeutics made up 0.01% of Flinton Capital Management's portfolio in Q3 2019, its #569 holding.
Flinton Capital Management first reported a position in Nektar Therapeutics in Q4 2016 and has held it in 12 quarters since.
Flinton Capital Management's Nektar Therapeutics position peaked at $3.42M in Q3 2018.
287 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on Flinton Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.